Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children-Reference-Cited by-同舟云学术

Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children

Published:2000-05 Issue:5 Volume:44 Page:1375-1376
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abreu Thalita¹,Plaisance Karen²,Rexroad Vivian³,Nogueira Susie¹,Oliveira Ricardo Hugo¹,Evangelista Lucia A.¹,Rangel Rosana¹,Silva Irene S.¹,Knupp Cathy⁴,Lambert John S.⁵

Affiliation:

1. Federal University of Rio de Janeiro, Rio de Janeiro, Brazil1;

2. School of Pharmacy,2 University of Maryland, and

3. Johns Hopkins Medical Institutions,3Baltimore, Maryland; and

4. Bristol-Myers-Squibb, Princeton, New Jersey4

5. Institute of Human Virology5 and

Abstract

ABSTRACT The bioavailability of didanosine at 180 mg/m 2 once daily was compared to that at 90 mg/m 2 twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0.95 ± 0.49, supporting the potential clinical adequacy of once-daily dosing.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.44.5.1375-1376.2000

Reference11 articles.

1. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children.;Balis F. M.;J. Infect. Dis.,1992

2. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.;Butler K. M.;N. Engl. J. Med.,1991

3. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials

4. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.;Gibb D.;Br. J. Clin. Pharmacol.,1995

5. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.;Hoetelmans R. M.;AIDS,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral Drugs in Pediatric HIV-Infected Patients;Pediatric Drugs;2011-06

2. Didanosine Population Pharmacokinetics in West African Human Immunodeficiency Virus-Infected Children Administered Once-Daily Tablets in Relation to Efficacy after One Year of Treatment;Antimicrobial Agents and Chemotherapy;2009-10

3. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children;Clinical Drug Investigation;2007

4. Pharmacokinetics of Antiretroviral Therapy in HIV-1-Infected Children;Clinical Pharmacokinetics;2005

5. Pharmacokinetics of Stavudine and Didanosine Coadministered with Nelfinavir in Human Immunodeficiency Virus-Exposed Neonates;Antimicrobial Agents and Chemotherapy;2001-12